GB0718167D0 - Cancer marker and therapeutic target - Google Patents

Cancer marker and therapeutic target

Info

Publication number
GB0718167D0
GB0718167D0 GB0718167A GB0718167A GB0718167D0 GB 0718167 D0 GB0718167 D0 GB 0718167D0 GB 0718167 A GB0718167 A GB 0718167A GB 0718167 A GB0718167 A GB 0718167A GB 0718167 D0 GB0718167 D0 GB 0718167D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic target
cancer marker
marker
cancer
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0718167A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0718167(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Priority to GB0718167A priority Critical patent/GB0718167D0/en
Publication of GB0718167D0 publication Critical patent/GB0718167D0/en
Priority to EP08806315.1A priority patent/EP2176664B1/en
Priority to DK12183760.3T priority patent/DK2535716T3/en
Priority to ES08806315.1T priority patent/ES2443541T3/es
Priority to AU2008300413A priority patent/AU2008300413B2/en
Priority to RU2010123921/15A priority patent/RU2529797C2/ru
Priority to CA2699702A priority patent/CA2699702C/en
Priority to PL12182790.1T priority patent/PL2533047T3/pl
Priority to ES12182790.1T priority patent/ES2588507T3/es
Priority to DK12182790.1T priority patent/DK2533047T3/en
Priority to PL08806315T priority patent/PL2176664T3/pl
Priority to US12/679,002 priority patent/US9134293B2/en
Priority to DK08806315.1T priority patent/DK2176664T3/da
Priority to EP12183760.3A priority patent/EP2535716B1/en
Priority to PCT/GB2008/003160 priority patent/WO2009037454A2/en
Priority to PL12183760T priority patent/PL2535716T3/pl
Priority to JP2010525420A priority patent/JP5774309B2/ja
Priority to ES12183760.3T priority patent/ES2612690T3/es
Priority to EP12182790.1A priority patent/EP2533047B1/en
Priority to RU2014128513A priority patent/RU2014128513A/ru
Priority to JP2015131752A priority patent/JP6234967B2/ja
Priority to US14/823,755 priority patent/US10261099B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
GB0718167A 2007-09-18 2007-09-18 Cancer marker and therapeutic target Ceased GB0718167D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
ES12183760.3T ES2612690T3 (es) 2007-09-18 2008-09-18 Marcador de cáncer y diana terapéutica
EP12182790.1A EP2533047B1 (en) 2007-09-18 2008-09-18 Ccr4 as therapeutic target for cancer
DK12182790.1T DK2533047T3 (en) 2007-09-18 2008-09-18 CCR4 as a therapeutic target for cancer
DK08806315.1T DK2176664T3 (da) 2007-09-18 2008-09-18 Ccr4 som cancermarkør
ES08806315.1T ES2443541T3 (es) 2007-09-18 2008-09-18 CCR4 como marcador de cáncer
AU2008300413A AU2008300413B2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
RU2010123921/15A RU2529797C2 (ru) 2007-09-18 2008-09-18 Раковый маркер и терапевтическая мишень
CA2699702A CA2699702C (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
PL12182790.1T PL2533047T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako cel terapeutyczny dla nowotworu
ES12182790.1T ES2588507T3 (es) 2007-09-18 2008-09-18 CCR4 como diana terapéutica para cáncer
EP08806315.1A EP2176664B1 (en) 2007-09-18 2008-09-18 Ccr4 as cancer marker
PL08806315T PL2176664T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako marker nowotworowy
US12/679,002 US9134293B2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
DK12183760.3T DK2535716T3 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
EP12183760.3A EP2535716B1 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
PL12183760T PL2535716T3 (pl) 2007-09-18 2008-09-18 Marker nowotworowy i cel terapeutyczny
JP2010525420A JP5774309B2 (ja) 2007-09-18 2008-09-18 癌マーカーおよび治療ターゲット
RU2014128513A RU2014128513A (ru) 2007-09-18 2014-07-14 Раковый маркер и терапевтическая мишень
JP2015131752A JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット
US14/823,755 US10261099B2 (en) 2007-09-18 2015-08-11 Cancer marker and therapeutic target

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target

Publications (1)

Publication Number Publication Date
GB0718167D0 true GB0718167D0 (en) 2007-10-31

Family

ID=38670078

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0718167A Ceased GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target

Country Status (11)

Country Link
US (2) US9134293B2 (https=)
EP (3) EP2176664B1 (https=)
JP (2) JP5774309B2 (https=)
AU (1) AU2008300413B2 (https=)
CA (1) CA2699702C (https=)
DK (3) DK2535716T3 (https=)
ES (3) ES2588507T3 (https=)
GB (1) GB0718167D0 (https=)
PL (3) PL2176664T3 (https=)
RU (2) RU2529797C2 (https=)
WO (1) WO2009037454A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
US20130095473A1 (en) * 2010-06-14 2013-04-18 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
HK1212389A1 (en) * 2011-10-24 2016-06-10 Signalchem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
MX356163B (es) 2011-12-01 2018-05-16 Chemocentryx Inc Anilinas sustituidas como antagonistas de ccr(4).
GB2512857A (en) 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
ES2884255T3 (es) 2013-11-06 2021-12-10 Janssen Biotech Inc Anticuerpos anti-CCL17
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
CA2962812A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
CN107624071A (zh) * 2015-04-17 2018-01-23 诺福泰克公司 肺癌治疗方法
US12366508B2 (en) 2015-07-30 2025-07-22 Qiagen Gmbh Method of preparing a frozen biological sample
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
JP7177445B2 (ja) * 2017-05-19 2022-11-24 真吾 前田 Ｃｃｒ４阻害による制御性ｔ細胞浸潤抑制法およびイヌの腫瘍性疾患の治療法
CN112601526B (zh) 2018-08-29 2025-10-03 凯莫森特里克斯股份有限公司 使用c-c趋化因子受体4(ccr4)拮抗剂和一种或多种检查点抑制剂的联合治疗
EP3885452A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
EP0689606A1 (en) * 1993-03-19 1996-01-03 The Johns Hopkins University ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
CN100455599C (zh) 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
EP1578341A2 (en) 2000-10-11 2005-09-28 Tularik Inc. Modulation of ccr4 function
EP1326617B9 (en) 2000-10-18 2006-10-25 Schering Aktiengesellschaft Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma
CA2439279A1 (en) 2001-02-28 2002-09-06 Protein Design Labs, Inc. Chemokine receptors and disease
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
NZ531069A (en) 2001-08-10 2007-01-26 Topigen Pharma Inc Methods for modulating viral infection of cells by modulating a binding interaction between a CCR1, CCR2, CCR3, CCR4, CCR5 and/or CCR8 receptor and a surface protein of the virus
PT1449850E (pt) 2001-08-31 2011-02-02 Kyowa Hakko Kirin Co Ltd Anticorpos humanos enxertados em rdc¿s e fragmentos desses anticorpos
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
US7919083B2 (en) 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
EP1592708A2 (en) * 2003-02-14 2005-11-09 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
EP1661889A4 (en) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
AU2004279739A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Composition of antibody capable of specifically binding CCR4
ATE486611T1 (de) 2003-12-04 2010-11-15 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8193159B2 (en) 2006-02-14 2012-06-05 Noxxon Pharma Ag MCP-1 binding nucleic acids
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
JP2010539508A (ja) 2010-12-16
DK2176664T3 (da) 2014-01-20
US10261099B2 (en) 2019-04-16
EP2533047B1 (en) 2016-05-11
DK2533047T3 (en) 2016-08-22
EP2176664B1 (en) 2013-11-06
EP2176664A2 (en) 2010-04-21
CA2699702A1 (en) 2009-03-26
AU2008300413A1 (en) 2009-03-26
US20160223572A1 (en) 2016-08-04
RU2529797C2 (ru) 2014-09-27
WO2009037454A3 (en) 2009-05-07
JP2015212703A (ja) 2015-11-26
US9134293B2 (en) 2015-09-15
CA2699702C (en) 2018-03-06
PL2176664T3 (pl) 2014-04-30
AU2008300413B2 (en) 2014-09-11
EP2535716B1 (en) 2016-11-02
RU2014128513A (ru) 2016-02-10
ES2443541T3 (es) 2014-02-19
ES2588507T3 (es) 2016-11-03
EP2535716A3 (en) 2013-03-13
ES2612690T3 (es) 2017-05-18
RU2010123921A (ru) 2011-12-20
WO2009037454A2 (en) 2009-03-26
PL2533047T3 (pl) 2016-11-30
EP2533047A1 (en) 2012-12-12
EP2535716A2 (en) 2012-12-19
US20100278844A1 (en) 2010-11-04
DK2535716T3 (en) 2017-02-13
PL2535716T3 (pl) 2017-06-30
JP5774309B2 (ja) 2015-09-09
JP6234967B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
GB0718167D0 (en) Cancer marker and therapeutic target
GB2447796B (en) Iodonitrobenzamide formulations for cancer and viral diseases
EP2225254A4 (en) THERAPEUTIC CARE TREATMENTS
EP2197533A4 (en) ABLATION OF PROSTATE CANCER
GB0717101D0 (en) Tumour marker
IL215373A0 (en) Spink1 as a prostate cancer marker and uses thereof
IL218118A0 (en) Target genes for cancer therapy
SI2155248T1 (sl) Ciljanje ABCB5 za zdravljenje raka
GB0519405D0 (en) Cancer therapy prognosis and target
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
GB0821537D0 (en) Therapeutic target
GB0700645D0 (en) Targets for disease therapy
GB0703654D0 (en) Sterimatic dose marker
GB0722773D0 (en) Cancer markers and uses thereof
GB0707417D0 (en) Cancer markers and uses thereof
GB0705517D0 (en) Therapeutic compounds and their use
GB0706538D0 (en) Cancer therapeutic
GB0701640D0 (en) Cancer target
GB0612259D0 (en) Cancer therapeutic
GB0421918D0 (en) Cancer therapeutic target
GB0612258D0 (en) Transcutaneous cancer therapeutic
GB0606703D0 (en) Transcutaneous cancer therapeutic
GB0706537D0 (en) Transcutaneous cancer therapeutic
GB0611130D0 (en) Cancer treatment
GB0700654D0 (en) Targets for disease therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)